A Biomarker Study of Solanezumab in Patients With and Without Alzheimer's

• Status: Completed
• Trial end date: 2012-08-01

Summary

The purpose of this trial is to compare the average change in the amount of amyloid beta species in blood after an infusion of solanezumab.

• Phase: Phase 2

Details

• Lead Sponsor: Eli Lilly and Company